Breast cancer, early
Invited discussant LBA13 and abstract 144O
Date
07 Oct 2016Session
Breast cancer, earlyPresenters
Marco ColleoniAuthors
M. ColleoniAuthor affiliations
- Istituto Europeo di Oncologia, 20141 - Milano/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
1351 - Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
Presenter: Xavier Pivot
Session: Breast cancer, early
Resources:
Abstract
Slides
4160 - Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population
Presenter: Christopher Hart
Session: Breast cancer, early
Resources:
Abstract
3576 - Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer
Presenter: Alberto Ocana Fernandez
Session: Breast cancer, early
Resources:
Abstract
Slides
3815 - Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
Presenter: Luisa Carbognin
Session: Breast cancer, early
Resources:
Abstract
3308 - Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
Presenter: Antonino Musolino
Session: Breast cancer, early
Resources:
Abstract
3802 - Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)
Presenter: Steven Shak
Session: Breast cancer, early
Resources:
Abstract
Slides
Invited discussant abstracts 151PD, 152PD, 153PD, 154PD
Presenter: Karen Gelmon
Session: Breast cancer, early
Resources:
Slides
Webcast
Invited discussant abstracts 145O and 146O
Presenter: Nadia Harbeck
Session: Breast cancer, early
Resources:
Slides
1602 - Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC)
Presenter: Sara Hurvitz
Session: Breast cancer, early
Resources:
Abstract
3679 - Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study
Presenter: Juan de la Haba
Session: Breast cancer, early
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.